The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

DICP, The Annals of Pharmacotherapy: Vol. 25, No. 5, pp. 478-484.
© 1991 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ariano, R.
Right arrow Articles by Zhanel, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ariano, R.
Right arrow Articles by Zhanel, G.

Research Articles

Antimicrobial prophylaxis in coronary bypass surgery: a critical appraisal

RE Ariano and GG Zhanel

The literature has been examined to assess the optimal prophylactic antimicrobial regimen for patients undergoing coronary bypass surgery. Antimicrobial surgical prophylaxis should be based on the two main potential pathogens, Staphylococcus epidermidis and S. aureus. It is unclear whether the prophylactic use of antimicrobials can or should be guided by in vitro antimicrobial susceptibility testing; data from well-performed clinical trials should be evaluated. The data fail to demonstrate consistently a significant difference within the cephalosporin class of antimicrobials with regard to prevention of infectious complications. Although it does not reach statistical difference, the trend with respect to efficacy appears to be cefuroxime, then cefamandole, and then cefazolin. The lack of significant difference among antimicrobials suggests an institution-individualized approach to the selection of the optimal antimicrobial for prophylaxis. For our facilities we recommend the following regimen: cefazolin sodium 1-2 g iv q8h for two days. There are not enough data at this time to recommend less than two days of antimicrobial prophylaxis for this type of surgery. In addition, aminoglycosides provide no added benefit when added to cephalosporins.


This article has been cited by other articles:


Home page
 Card Surg AdultHome page
E. Gongora and T. M. Sundt III
Myocardial Revascularization with Cardiopulmonary Bypass
Card. Surg. Adult, January 1, 2008; 3(2008): 599 - 632.
[Full Text]

Home page
 Ann. Thorac. Surg.Home page
E. K. Fellinger, B. J. Leavitt, and J. C. Hebert
Serum levels of prophylactic cefazolin during cardiopulmonary bypass surgery
Ann. Thorac. Surg., October 1, 2002; 74(4): 1187 - 1190.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
K. A. Eagle, R. A. Guyton, R. Davidoff, G. A. Ewy, J. Fonger, T. J. Gardner, J. P. Gott, H. C. Herrmann, R. A. Marlow, W. C. Nugent, et al.
ACC/AHA guidelines for coronary artery bypass graft surgery: A report of the American College of Cardiology/ American Heart Association task force on Practice Guidelines (Committee to revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery)
J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1262 - 1347.
[Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1991 by Harvey Whitney Books Company.